
Poly Medicure (POLYMED) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
4.4B
Gross Profit
2.9B
66.56%
Operating Income
984.3M
22.33%
Net Income
918.3M
20.83%
Balance Sheet Metrics
Total Assets
31.9B
Total Liabilities
4.3B
Shareholders Equity
27.7B
Debt to Equity
0.15
Cash Flow Metrics
Revenue & Profitability Trend
Poly Medicure Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 16.7B | 13.7B | 11.1B | 9.2B | 7.8B |
Cost of Goods Sold | 5.5B | 6.0B | 5.1B | 4.3B | 3.4B |
Gross Profit | 11.2B | 7.6B | 6.0B | 4.8B | 4.4B |
Gross Margin % | 66.8% | 55.8% | 54.1% | 52.8% | 56.6% |
Operating Expenses | |||||
Research & Development | 245.7M | 189.6M | 178.0M | 187.7M | 131.4M |
Selling, General & Administrative | - | 473.2M | 380.9M | 322.4M | 294.6M |
Other Operating Expenses | 3.4B | 922.6M | 721.8M | 559.9M | 457.2M |
Total Operating Expenses | 3.6B | 1.6B | 1.3B | 1.1B | 883.3M |
Operating Income | 3.7B | 3.0B | 2.2B | 1.6B | 1.7B |
Operating Margin % | 22.2% | 22.2% | 19.6% | 17.9% | 22.0% |
Non-Operating Items | |||||
Interest Income | - | 118.4M | 59.7M | 22.9M | 33.7M |
Interest Expense | 120.0M | 118.6M | 85.4M | 37.2M | 77.4M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 4.5B | 3.4B | 2.4B | 2.0B | 1.8B |
Income Tax | 1.1B | 860.1M | 582.1M | 487.4M | 441.8M |
Effective Tax Rate % | 25.2% | 25.0% | 24.5% | 25.0% | 24.5% |
Net Income | 3.4B | 2.6B | 1.8B | 1.5B | 1.4B |
Net Margin % | 20.3% | 18.9% | 16.2% | 16.0% | 17.5% |
Key Metrics | |||||
EBITDA | 5.5B | 4.0B | 3.1B | 2.4B | 2.3B |
EPS (Basic) | - | ₹26.92 | ₹18.69 | ₹15.28 | ₹15.25 |
EPS (Diluted) | - | ₹26.90 | ₹18.67 | ₹15.27 | ₹15.24 |
Basic Shares Outstanding | - | 95946790 | 95916495 | 95888694 | 89083537 |
Diluted Shares Outstanding | - | 95946790 | 95916495 | 95888694 | 89083537 |
Income Statement Trend
Poly Medicure Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 87.0M | 120.5M | 70.6M | 77.6M | 49.5M |
Short-term Investments | 12.1B | 2.7B | 2.9B | 3.4B | 3.7B |
Accounts Receivable | 3.5B | 2.7B | 2.4B | 2.1B | 1.6B |
Inventory | 2.9B | 2.2B | 2.1B | 1.7B | 1.3B |
Other Current Assets | 655.8M | 178.5M | 262.0M | 230.7M | 165.8M |
Total Current Assets | 19.2B | 8.4B | 8.1B | 7.8B | 7.0B |
Non-Current Assets | |||||
Property, Plant & Equipment | 10.4B | 37.1M | 24.7M | 11.5M | 21.7M |
Goodwill | 837.8M | 821.6M | 787.1M | 792.4M | 799.9M |
Intangible Assets | 266.1M | 249.9M | 215.5M | 220.7M | 228.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 489.2M | -1.0K | -2.0K | 1.0K | 81.1M |
Total Non-Current Assets | 12.8B | 10.2B | 7.7B | 5.9B | 5.2B |
Total Assets | 31.9B | 18.6B | 15.8B | 13.8B | 12.2B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 864.2M | 956.0M | 923.1M | 890.4M | 645.2M |
Short-term Debt | 1.8B | 1.7B | 1.3B | 882.0M | 721.8M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 289.8M | 283.9M | 3.0K | 230.7M | -1.0K |
Total Current Liabilities | 3.7B | 3.5B | 2.9B | 2.3B | 1.7B |
Non-Current Liabilities | |||||
Long-term Debt | 7.7M | 20.9M | 188.5M | 385.1M | 641.6M |
Deferred Tax Liabilities | 428.7M | 244.8M | 154.3M | 161.3M | 130.4M |
Other Non-Current Liabilities | -1.0K | 11.2M | 1.0K | -1.0K | 11.5M |
Total Non-Current Liabilities | 566.3M | 373.8M | 422.8M | 626.8M | 867.6M |
Total Liabilities | 4.3B | 3.9B | 3.4B | 2.9B | 2.6B |
Equity | |||||
Common Stock | 506.6M | 479.9M | 479.7M | 479.5M | 479.4M |
Retained Earnings | - | 7.3B | 5.3B | 4.0B | 3.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 27.7B | 14.7B | 12.4B | 10.9B | 9.7B |
Key Metrics | |||||
Total Debt | 1.8B | 1.7B | 1.5B | 1.3B | 1.4B |
Working Capital | 15.5B | 4.9B | 5.1B | 5.6B | 5.3B |
Balance Sheet Composition
Poly Medicure Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 4.5B | 3.4B | 2.4B | 2.0B | 1.8B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -1.5B | -446.6M | -545.1M | -887.2M | -607.3M |
Operating Cash Flow | 3.0B | 2.9B | 1.8B | 954.6M | 1.2B |
Investing Activities | |||||
Capital Expenditures | -3.3B | -2.8B | -2.4B | -1.5B | -945.2M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | -3.4B |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -3.3B | -2.8B | -2.4B | -1.5B | -4.4B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -303.4M | -287.4M | -239.7M | -239.2M | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 9.7B | -284.8M | -236.2M | -238.2M | 4.0B |
Free Cash Flow | -906.1M | -109.3M | -482.2M | -321.1M | 236.0M |
Net Change in Cash | 9.4B | -100.0M | -824.4M | -824.2M | 835.7M |
Cash Flow Trend
Poly Medicure Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
56.51
Forward P/E
250.96
Price to Book
7.17
Price to Sales
11.70
PEG Ratio
250.96
Profitability Ratios
Profit Margin
20.28%
Operating Margin
22.33%
Return on Equity
15.99%
Return on Assets
9.16%
Financial Health
Current Ratio
5.18
Debt to Equity
6.52
Beta
0.04
Per Share Data
EPS (TTM)
₹34.11
Book Value per Share
₹268.63
Revenue per Share
₹168.34
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
polymed | 195.3B | 56.51 | 7.17 | 15.99% | 20.28% | 6.52 |
Dr Agarwal's Health | 140.4B | 625.56 | 7.45 | 6.61% | 4.88% | 49.87 |
Laxmi Dental | 21.8B | 64.42 | 10.33 | 25.70% | 13.29% | 9.35 |
Tarsons Products | 19.9B | 66.74 | 3.15 | 4.79% | 7.59% | 53.82 |
Prevest Denpro | 6.7B | 36.86 | 6.35 | 18.70% | 28.81% | 0.00 |
Centennial Surgical | 558.2M | 2,482.50 | 1.82 | -4.65% | -2.74% | 108.97 |
Financial data is updated regularly. All figures are in the company's reporting currency.